Details

Autor(en) / Beteiligte

• Beach, Thomas G
• Adler, Charles H
• Zhang, Nan
• Serrano, Geidy E
• Sue, Lucia I
• Driver-Dunckley, Erika
• Mehta, Shayamal H
• Zamrini, Edouard E
• Sabbagh, Marwan N
• Shill, Holly A
• Belden, Christine M
• Shprecher, David R
• Caselli, Richard J
• Reiman, Eric M
• Davis, Kathryn J
• Long, Kathy E
• Nicholson, Lisa R
• Intorcia, Anthony J
• Glass, Michael J
• Walker, Jessica E
• Callan, Michael M
• Oliver, Javon C
• Arce, Richard
• Gerkin, Richard C
• Ginsberg, Stephen D.

Titel

Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia

Ist Teil von

• PloS one, 2020-04, Vol.15 (4), p.e0231720-e0231720

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Many subjects with neuropathologically-confirmed dementia with Lewy bodies (DLB) are never diagnosed during life, instead being categorized as Alzheimer's disease dementia (ADD) or unspecified dementia. Unrecognized DLB therefore is a critical impediment to clinical studies and treatment trials of both ADD and DLB. There are studies that suggest that olfactory function tests may be able to distinguish DLB from ADD, but few of these had neuropathological confirmation of diagnosis. We compared University of Pennsylvania Smell Identification Test (UPSIT) results in 257 subjects that went on to autopsy and neuropathological examination. Consensus clinicopathological diagnostic criteria were used to define ADD and DLB, as well as Parkinson's disease with dementia (PDD), with (PDD+AD) or without (PDD-AD) concurrent AD; a group with ADD and Lewy body disease (LBD) not meeting criteria for DLB (ADLB) and a clinically normal control group were also included. The subjects with DLB, PDD+AD and PDD-AD all had lower (one-way ANOVA p < 0.0001, pairwise Bonferroni p < 0.05) first and mean UPSIT scores than the ADD, ADLB or control groups. For DLB subjects with first and mean UPSIT scores less than 20 and 17, respectively, Firth logistic regression analysis, adjusted for age, gender and mean MMSE score, conferred statistically significant odds ratios of 17.5 and 18.0 for the diagnosis, vs ADD. For other group comparisons (PDD+AD and PDD-AD vs ADD) and UPSIT cutoffs of 17, the same analyses resulted in odds ratios ranging from 16.3 to 31.6 (p < 0.0001). To our knowledge, this is the largest study to date comparing olfactory function in subjects with neuropathologically-confirmed LBD and ADD. Olfactory function testing may be a convenient and inexpensive strategy for enriching dementia studies or clinical trials with DLB subjects, or conversely, reducing the inclusion of DLB subjects in ADD studies or trials.